In the next 5 years, what outcome is most likely for FDA management of accelerated approvals with subsequent failed confirmatory trials?

Status quo with extended review timelines and limited FDA authority
% (7 votes)
Increased pharmaceutical manufacturer voluntary actions
% (1 votes)
Legislative change leading to additional FDA authority and actions
% (3 votes)